Skip to content

Ssci-wiki, home

Home~about/pipeline/about Resources/resources Suppliers/sources Community/links Neural View/neural

the sci-wiki Forum + Talk/forum

periodic table/compounds/table compare/compounds/compare by effect/effects collections/collections comparisons/vs interactions + stacks/stacks database/database

support the wikikeeps it ad free

Loading…

~$the sci-wiki

the ultimate user-report oriented database of all things psychopharma

scientificsean@proton.me

Explore

Home
about/pipeline
Resources
Suppliers
Community
Neural View
the sci-wiki
Forum + Talk

Follow

discord

this stays freeNo ads, no paywall, no account. If it has been useful, a contribution keeps the servers on and the research going; nothing here is ever locked behind one.support

all information here is purely educational and research-oriented only. this is not medical advice in any capacity.

nothing here is written by a doctor, medical professional, or scientist in any capacity; purely by an independent researcher studying neuroscience. nobody is liable for misuse of these chemicals or injury done except for the user themselves. all information is purely here for safety reasons.

links to websites may be affiliate links. please do note. using the outlets + codes here helps keep this free, additionally giving you a discount. thank you

© 2026 Scientific Sean. All rights reserved.rss

for educational and safety purposes

Loading…

the sci-wiki/effects/Attention

Attention

Every compound in the sci-wiki that affects attention; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.

1 sourced · 25 reference

←attention26/26filter this drawer by compound name

GB-115

GB-115 is a cleverly designed dipeptide anxiolytic that eases anxiety while keeping the mind clear, a combination almost nothing else in its category manages. Rather than sedating, it blocks the cholecystokinin CCK-1 receptor, a pathway tied specifically to chronic anxiety and panic, and in a clinical study of generalized anxiety disorder it actually sharpened attention and reaction time while it worked. For those seeking calm without the fog, weakness, or dependence of classic sedatives, GB-115 is a genuinely intriguing research anxiolytic.

reference shelf; no outlet carries these yet

Viloxazine

Viloxazine, sold as extended-release Qelbree, is a non-stimulant ADHD medication approved for children, adolescents, and adults. It works mainly as a norepinephrine reuptake inhibitor with additional serotonergic modulation and is not a controlled substance; however, it carries an FDA boxed warning for suicidal thoughts and behaviors and is a strong CYP1A2 inhibitor with important drug interactions.

ABT-089

ABT-089, also known as pozanicline, is a synthetic small molecule that acts as a partial agonist at neuronal nicotinic acetylcholine receptors, with selectivity for the α4β2 subtype. Developed by Abbott Laboratories, it was investigated as a cognitive enhancer and as a candidate treatment for attention-deficit/hyperactivity disorder (ADHD) and other cognitive conditions.

ABT-126

ABT-126 was AbbVie's (formerly Abbott's) selective alpha7 nicotinic acetylcholine receptor agonist, developed for both cognitive impairment in schizophrenia and Alzheimer's disease. The alpha7 receptor is heavily expressed on hippocampal and prefrontal circuits involved in learning and attention, and it was a hot target through the 2010s after epidemiological observations tied smoking to modest cognitive benefits in schizophrenia patients. A Phase 2 trial found a real procognitive signal, but only in nonsmokers; smokers, whose alpha7 receptors were presumably already saturated or desensitized by nicotine, showed nothing. A larger Phase 2b confirmatory trial in nonsmokers, and a separate one in smokers, both failed to show meaningful benefit, and AbbVie discontinued the program around 2016 along with much of the industry's broader retreat from alpha7 agonists.

ABT-239

Abbott Laboratories built ABT-239 as a drug-like, orally active histamine H3 antagonist with real human-development ambitions behind it, unlike most H3 tool compounds; it was investigated as a candidate for ADHD, Alzheimer's disease, and schizophrenia-related cognitive deficits. It bound the human H3 receptor with subnanomolar potency and more than 1000-fold selectivity over the other histamine receptor subtypes, and it worked in rodent cognition and stress models. Abbott dropped it from human trials after it showed QT interval prolongation, a cardiac liability serious enough to end clinical plans outright, and ABT-239 has since lived on purely as a widely used preclinical benchmark for newer H3 antagonists.

Androstadienone

Androstadienone (androsta-4,16-dien-3-one) is an endogenous volatile C19 16-androstene steroid found in male axillary sweat, semen, saliva and plasma, and the most intensively studied candidate human chemosignal or "pheromone." It is not a classical ion-channel neurosteroid; its central actions are triggered peripherally through the main olfactory epithelium, where the odorant receptor OR7D4 (a G-protein-coupled receptor) is the principal transducer and its genetic variation explains much of the wide person-to-person difference in whether the compound smells sweaty, urinous, sweet or nothing at all. Controlled exposure has been reported to modulate mood, sustained attention, salivary cortisol, autonomic tone and hypothalamic and frontolimbic activity, often in a sex-dependent and strongly context-dependent way. The evidence base is large but contested; effect sizes are small and several findings have failed to replicate, so the compound remains a putative rather than a proven pheromone.

Bavisant

Bavisant started life at Johnson & Johnson as JNJ-31001074, a potent, brain-penetrant histamine H3 antagonist aimed at adult ADHD; a controlled dose-ranging trial found it did not produce a clinically meaningful benefit over placebo, and J&J's ADHD program quietly closed. The molecule's story did not end there. BenevolentAI, an AI-driven drug discovery company, later licensed the same compound, renamed it bavisant, and repositioned it around a side effect noted in the original data, dose-dependent insomnia, betting that the same wake-promoting H3 blockade could help excessive daytime sleepiness in Parkinson's disease instead. That reran the drug through a Phase IIb trial testing three doses against placebo in roughly 230 Parkinson's patients, an unusually direct case of an abandoned CNS candidate getting a second clinical life through indication-hopping rather than fresh chemistry.

Centanafadine

A once-daily reuptake inhibitor of norepinephrine, dopamine and serotonin, approved July 2026 for ADHD in adults and children aged 6 and older.

Ciproxifan

Ciproxifan never had a pharma sponsor chasing an indication; it exists almost entirely as an academic tool compound, and it became the reference histamine H3 antagonist that an entire generation of sleep, attention, and Alzheimer's-related rodent studies were built around. Its defining quirk is species selectivity: it binds rodent H3 receptors in the subnanomolar range but only moderately at the human receptor, which is exactly why it stayed a lab reagent instead of becoming a clinical candidate. Later work found it also reversibly inhibits monoamine oxidase A and B, an unplanned second mechanism that complicates interpreting some of the older behavioral data attributed purely to H3 blockade.

CX-516

CX-516 (Ampalex) is the first-in-class ampakine, developed by Cortex Pharmaceuticals, historically important as the compound that established AMPA-receptor positive modulation as a cognition strategy. It facilitates long-term potentiation and memory in animal models, but its weak potency and short half-life undermined every human trial.

CX-717

CX-717 is a later, more brain-penetrant ampakine (Cortex Pharmaceuticals, later RespireRx) notable for offsetting sleep-deprivation cognitive decline in nonhuman primates and, at high dose, in humans, plus a distinct adult-ADHD development track. It has a 'low-impact' AMPA-PAM profile.

Eptastigmine

Eptastigmine was the Italian pharmaceutical company Mediolanum's long-acting redesign of physostigmine, an old carbamate cholinesterase inhibitor whose natural form works but wears off too fast to dose conveniently; adding a heptyl (seven-carbon) chain extended its duration of action enough to make once- or twice-daily dosing plausible for Alzheimer's patients. It moved through a full decade of pharmacology, toxicology, and clinical study, including efficacy trials that showed genuine cognitive benefit over placebo. Then hematology data caught up with it, reversible neutropenia and, in a subset of patients, agranulocytosis (a dangerous collapse in infection-fighting white blood cells) showed up during clinical trials at a rate high enough that regulators would not accept the risk, and the program was discontinued despite a decade of otherwise promising work.

GSK189254

GlaxoSmithKline built GSK189254 out of a benzazepine chemical series distinct from the imidazole-based H3 antagonists that came before it, and it turned into one of the field's most cited cognition tool compounds. It binds human H3 receptors with subnanomolar affinity and more than 10,000-fold selectivity over other targets tested, and PET-style binding studies confirmed it engages H3 receptors directly in postmortem Alzheimer's disease brain tissue. In rodents it raised acetylcholine, noradrenaline, and dopamine release in the cortex and hippocampus and improved performance across passive avoidance, water maze, object recognition, and attentional set-shifting tasks, a strong enough preclinical package that GSK explored it for Alzheimer's-related cognitive symptoms; it never emerged as a named clinical program, and the compound is now used mainly as a research standard rather than a drug candidate.

HTL0018318

A selective M1 partial agonist from Heptares that improved memory and attention in healthy volunteers and Alzheimer's patients, and was halted in 2018 over a tumour finding in monkeys rather than anything seen in people.

Ispronicline

Ispronicline traces its chemistry back to nicotine research originally funded by tobacco company R.J. Reynolds, which spun off its pharmaceutical research arm into Targacept in the late 1990s. The resulting compound was a partial agonist at alpha4beta2 neuronal nicotinic receptors, designed to capture nicotine's attention- and memory-enhancing effects without its addictive and cardiovascular baggage. AstraZeneca partnered with Targacept and pushed ispronicline (as AZD3480) into a Phase IIb dose-finding trial for mild-to-moderate Alzheimer's disease as well as separate studies for adult ADHD. The Alzheimer's trial, published in 2011, failed to show a robust cognitive benefit, and AstraZeneca discontinued the partnership around 2010-2011, part of a broader collapse of the nicotinic-receptor cognition-enhancement field that also claimed several competing programs.

Linopirdine

Linopirdine took a completely different route to boosting acetylcholine than anything else in this collection; instead of blocking the enzyme that breaks ACh down, DuPont built it to block KCNQ2/KCNQ3 potassium channels, the so-called M-channel, which in turn triggers broad neurotransmitter release, acetylcholine included, across the brain. Preclinical work in the late 1980s looked strong enough that DuPont pushed it into Alzheimer's clinical trials, but the results in patients were equivocal; the drug needed high doses to meaningfully block the M-current, and those doses caused cholinergic overstimulation side effects like tremor. The program was ultimately discontinued, but linopirdine's real legacy is scientific rather than commercial, it became the founding tool compound for an entire generation of KCNQ channel research, directly enabling more selective descendants like XE-991 and eventually helping validate KCNQ as a target that led to the anticonvulsant retigabine.

Metrifonate

Metrifonate has one of the stranger backstories in Alzheimer's drug history; it started life decades earlier as an antischistosomal insecticide-derived organophosphate sold as Bilarcil, and only later did researchers realize its slow, pseudo-irreversible acetylcholinesterase inhibition made it a candidate for boosting acetylcholine in Alzheimer's disease. Bayer ran it through large placebo-controlled Phase III trials where it produced genuine, statistically significant cognitive improvement over placebo, real efficacy that few of its competitors in this archive ever achieved. Then, deep into trials, roughly twenty patients developed neuromuscular dysfunction and life-threatening respiratory paralysis, apparently related to how chronic organophosphate exposure sensitizes patients to subsequent anesthetic or neuromuscular-blocking agents; Bayer halted the program and withdrew its FDA application in 1997, turning a drug with real cognitive benefit into a cautionary tale about repurposing organophosphates for chronic dosing.

Milameline

Milameline was Parke-Davis and Roussel-Uclaf's shot at treating Alzheimer's disease by stimulating muscarinic receptors directly instead of propping up acetylcholine with a cholinesterase inhibitor. It is a partial agonist with roughly equal affinity at all five muscarinic subtypes, which was the deliberate choice: no subtype selectivity, just enough intrinsic activity to signal without saturating the system. The preclinical package was strong for its era. It reversed spatial memory deficits in rats with lesioned forebrain cholinergic neurons, raised cortical blood flow, desynchronised the EEG in both rats and rhesus monkeys in the pattern that reads as increased arousal, and rescued scopolamine-impaired attention in monkeys. Then the dose window closed. In Alzheimer's patients, 1 mg every six hours was fine, 2 mg was tolerated by most people, and 2.5 to 3 mg brought sweating, hypersalivation, nausea, diarrhoea, hypotension and, notably, parkinsonian signs including cogwheeling, tremor and a shuffling gait; that study was stopped after the fourth 3 mg dose. The pivotal 52-week trial across 38 centres was then terminated early when an interim analysis projected it would not work. It never worked, and it was never approved.

MK-0777

MK-0777 was a Merck compound built to be a benzodiazepine-like drug without the sedation; it selectively potentiated GABA-A receptors carrying the alpha2 or alpha3 subunit instead of hitting alpha1 (the subunit responsible for benzodiazepine sedation and abuse liability). The idea came out of University of Pittsburgh postmortem work showing that GABA neurotransmission onto pyramidal cells in the schizophrenic prefrontal cortex is weakened, which was proposed as a root cause of the working-memory deficits in the disease. A small 2008 open-label-adjacent proof-of-concept trial in chronic schizophrenia patients found real improvements on working-memory tasks and increased frontal gamma power, which made a fair bit of noise in the field. A larger, properly randomized follow-up then failed to replicate the benefit, and Merck quietly let the program lapse; it never advanced past early Phase II.

NS-2359

NS-2359 (GSK372475) is a triple monoamine reuptake inhibitor with approximately equipotent blockade of the dopamine, norepinephrine, and serotonin transporters, originally developed by NeuroSearch and licensed to GlaxoSmithKline [1]. It was investigated as a broad-spectrum antidepressant and for other neuropsychiatric indications, but two controlled trials in major depressive disorder found it neither efficacious nor well tolerated [1].

PQCA

A selective M1 positive allosteric modulator from Merck, used as the reference preclinical tool for the claim that boosting acetylcholine at M1 alone improves cognition without the gut effects of a cholinesterase inhibitor.

Rolziracetam

Rolziracetam was developed as CI-911 during the 1980s racetam research wave that piracetam's success touched off across European and American pharma chemistry, one of many cyclic-imide/pyrrolidinone analogs screened for "amnesia-reversal" activity against scopolamine-induced memory deficits in rodents, the field's standard nootropic assay at the time. It performed in that classic screening model and had its metabolic disposition characterized in animal studies, but like most second-generation racetams it never accumulated the human efficacy data needed to reach market. The entire racetam class shared the same problem: a diffuse, hard-to-pin-down mechanism that made regulatory approval an uphill argument, and once the pharmaceutical industry's attention moved to more mechanistically defined drug classes, compounds like rolziracetam simply stopped being worth developing further.

Sabcomeline

Sabcomeline was SmithKline Beecham's most clinically advanced muscarinic-agonist candidate for Alzheimer's disease, marketed in development under the name Memric, and it made it further than most of its rivals in this slice, all the way to Phase III. It bound all five muscarinic receptor subtypes with similar raw affinity but showed functional selectivity for M1 in both cell assays and animal behavior, reversing delay-induced memory deficits in marmosets and rats at doses well below those that triggered cholinergic side effects. Despite genuinely promising early signals of symptomatic benefit in Alzheimer's patients without provoking overt cholinergic toxicity, the Phase III program ultimately produced disappointing results and SmithKline Beecham shelved it, one more entry in the long list of muscarinic-agonist Alzheimer's drugs that looked good on paper and in monkeys but not in a pivotal trial.

Tacrine

Tacrine earns its spot in this archive on historical weight rather than obscurity; it was the first drug the FDA ever approved for Alzheimer's disease, launched in 1993 under the name Cognex and proof-of-concept that the cholinergic hypothesis (that boosting acetylcholine could meaningfully help Alzheimer's symptoms) actually worked in the clinic, opening the door for donepezil, rivastigmine, and galantamine to follow. That legacy came with a real cost; tacrine caused liver-enzyme elevations in roughly a quarter to half of treated patients, serious enough that trial protocols required stopping the drug if ALT rose above three times normal, and while the injury was almost always reversible on discontinuation, the burden of mandatory liver monitoring made tacrine impractical once safer, twice-a-day alternatives without the hepatotoxicity reached the market. Its manufacturer discontinued marketing tacrine in the United States in 2013, quietly retiring the drug that had started the entire cholinesterase-inhibitor era.

TAK-071

TAK-071 is Takeda's M1 muscarinic positive allosteric modulator, built around a deliberately low cooperativity value on the finding that cooperativity, not potency, is what decides whether an M1 drug causes diarrhoea; it reached a phase 2 crossover trial in Parkinson disease where it missed its gait endpoint and improved a secondary cognitive measure.

Xanomeline

An M1/M4-preferring muscarinic agonist that failed as an Alzheimer's drug in the 1990s and returned in 2024 as the active antipsychotic half of Cobenfy, the first schizophrenia treatment approved without dopamine receptor blockade.